TY - JOUR AU - Dudley J. Pennell, AU - John B. Porter, AU - Maria Domenica Cappellini, AU - Lee Lee Chan, AU - Amal El-Beshlawy, AU - Yesim Aydinok, AU - Hishamshah Ibrahim, AU - Chi-Kong Li, AU - Vip Viprakasit, AU - Mohsen S. Elalfy, AU - Antonis Kattamis, AU - Gillian Smith, AU - Dany Habr, AU - Gabor Domokos, AU - Bernard Roubert, AU - Ali Taher, PY - 2012/06/04 Y2 - 2024/03/28 TI - Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major JF - Haematologica JA - haematol VL - 97 IS - 6 SE - Articles DO - 10.3324/haematol.2011.049957 UR - https://haematologica.org/article/view/6321 SP - 842-848 AB - Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important.Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years.Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P